Historical Pathogen-Driven Selection May Contribute to Contemporary Ethnic Difference in Bladder Cancer Susceptibility

INTRODUCTION

Bladder cancer (BCa) is the most common malignancy of the human urinary system, and the 6th most common cancer in all sites [1]. Established risk factors for BCa include age, male sex, tobacco smoking, and exposure to certain occupational hazards. It has also been noted that different ethnic populations have different susceptibilities to BCa; a factor which may have contributed to the geographic variability of BCa incidence [2]. The mechanism for this ethnic difference, however, remains unknown.

APOBEC-mediated mutagenesis contributes to the majority (∼70%) of the mutation burden in BCa tumors [3–5]. APOBEC3 mutagens (particularly, APOBEC3A and APOBEC3B) played a crucial role in BCa carcinogenesis through the introduction of hotspot driver mutations in major BCa oncogenes and tumor suppressor genes [4]. An APOBEC3-related common genetic variant, rs1014971, a C>T substitution at position 39332623 of chr22 (hg19), was identified as being associated not only with BCa risk, but also with APOBEC3 gene expression and the APOBEC-mutagenesis burden in BCa tumors [6]. APOBEC3 enzymes are essential in the body’s defense against pathogens, particularly retroviruses (e.g., HIV) which have exerted a strong selective pressure in human evolution [7]. These proteins have undergone rapid evolution, driven by the pathogen-host arms race [7]. It is also recognized that a variety of the infectious agents historically encountered by populations across different regions have resulted in various local adaptations of the pathogen-defense system, and empirical evidence has suggested a link between ancient pathogen invasions and contemporary susceptibility to diseases, such as certain metabolic and autoimmune disorders [8–10]. Given these findings, we hypothesized that the present-day ethnic variation in BCa susceptibility could be because APOBEC3-variants were differentially selected among ethnic populations during human evolution.

MATERIALS AND METHODS

RESULTS AND DISCUSSION

First of all, we validated the differences in BCa incidence across ethnic groups, based on the estimated age-adjusted incidence rates using the US Surveillance, Epidemiology, and End Results data. A substantial difference in incidence was observed in ethnic groups overall, and also between groups stratified by age and sex, with Caucasians at a >2-folds risk as compared to Asians / Pacific islanders (Fig. 1A–C). We next calculated the ancestry-specific prevalence of the alternative allele of APOBEC3-rs1014971 in contemporary populations, using 1000Genomes (TGP) data. Interestingly, the T allele, associated with both increased BCa risk and APOBEC mutagenesis burden in BCa tumors, presented at a much higher frequency in Caucasians (65%) as opposed to Asians (35% in South Asian and 28% in East Asian) (Fig. 1D) [6]. We then analyzed the ethnic distribution of the APOBEC mutagenesis burden, using the whole-exome-seq somatic mutation BCa cohort (n = 602) compiled in our previous work [4]. Coherently, a much higher APOBEC-mutagenesis burden was observed in Caucasians than in other ethnic groups for both non-muscle-invasive and muscle-invasive BCa tumors (Fig. 1E-F). We also considered whether such differences in global APOBEC-mutagenesis would further lead to differential mutation profiles in BCa-driver genes across ethnic groups. In our previous work, FGFR3 S249C has been shown to be induced by APOBEC among all recurrent mutations in the BCa driver gene FGFR3 [3, 18]. The current study notably found that the proportion of FGFR3 S249C in BCa tumors bearing recurrent FGFR3 mutations was significantly higher in Caucasian than in East Asian BCa patients (Chi-squared test, P = 5.0×10^–4; Fig. 1G). This was further verified in additional targeted-sequencing samples and meta-analyses of WES and targeted-sequencing cohorts (targeted-sequencing, S249C prevalence in 257 Caucasians vs. 10 Asians with FGFR3 recurrent mutations, OR = 1.99, P = 0.32; meta-analysis of WES and targeted-sequence samples, OR = 3.34, P = 0.002; Table S1 and Fig. S1). In contrast, RAS mutations (HRAS and KRAS genes) that were basically associated with non-APOBEC mutagenic processes were found in a much lower proportion in Caucasian than in Asian BCa patients (Chi-squared test, P = 4.7×10^–4; Fig. 1H and Fig. S2). These findings suggest that the APOBEC3-related rs1014971 was not only involved in the different BCa risk profiles and APOBEC-mutagenesis burden, but also associated with the divergent mutational profiles in mechanistically pivotal BCa-driver genes across ethnic groups.

OPEN IN VIEWER

Fig. 1

Ethnic profiles of BCa susceptibility, BCa-related APOBEC3-variants rs1014971, APOBEC-induced mutation burden, FGFR3 and RAS gene mutation status, and the natural selection and ancient genome dynamics of APOBEC3-rs1014971. (A– C) Ethnic differences in BCa-incidence rate and 95% confidence intervals revealed in US Surveillance, Epidemiology, and End Results (SEER) data. * indicates non-Hispanic ethnicity. (D) Ethnic difference in rs1014971-T allele frequency in 1000Genomes populations (Sample size, n = 5,008). (E-F) Ethnic difference in APOBEC-mutagenesis burden in whole-exome-seq BCa cohort (n = 602). NMIBC, non-muscle-invasive bladder cancer; MIBC, muscle-invasive bladder cancer. (G) Proportion of FGFR3 S249C vs. other recurrent FGFR3 mutations in BCa tumors bearing recurrent FGFR3 mutations across ethnic groups. (H) Mutation status in RAS genes (HRAS and KRAS) in BCa tumors across ethnic groups. (I) Fu & Li’s D and F statistics for test of neutrality in 1000Genomes populations, shown respectively in the upper and lower panel. A value <0 indicates potential natural selection. The dashed lines represent thresholds of statistical significance (α= 0.05). EUR, European; AMR, American; AFR, African; SAS, South Asian; EAS, East Asian. (J) Joint analysis of current (TGP, n = 2,504) and ancient (AADR 1240K, n = 4,092) genomes regarding rs1014971 allele distribution. Upper part, odds ratios of rs1014971-T allele frequency between current vs. ancient samples. Lower part, chronological dynamics of rs1014971-T allele frequency in ancient human genomes of West Eurasian origin, by 1k-year unit. n_a, number of ancient genomes analyzed.

In view of the fact that the rs1014971 is a common variant with strong ethnic heterogeneity in contemporary human beings, and that APOBEC3 enzymes play crucial roles in immunity and pathogen restriction, we further explored whether the distribution of its alleles was potentially shaped by the history of human evolution. Non-neutral signatures of skews in the site-frequency spectrum were identified using the D _FL and F _FL metrics. These two metrics are population-genetic parameters commonly used to test the likelihood that a given genetic variant is under natural selection, and a negative value surpassing the threshold of statistical significance suggests influence by natural selection (Fig. 1I, upper for D _FL and lower for F _FL , respectively). Moreover, the joint analysis of contemporary (TGP data, n = 2,504) and ancient human genomes (Allen Ancient DNA Resource, AADR 1240K data; n = 4,072) showed a significantly higher frequency of the alternative allele [T] in contemporary populations than in ancient populations in the Americas, whereas a lower frequency was found in contemporary Asian populations than in their ancient counterparts (Americas, OR = 2.77, 95% CI = [2.20, 3.50], P = 5.9×10^–18; South Asia, OR = 0.42, 95% CI = [0.30, 0.57], P = 2.4×10^–8; East Asia, OR = 0.56, 95% CI = [0.46, 0.69], P = 1.4×10^–11; Fig. 1J, upper part; Table S2). Although the rs1014971-T allele frequency was globally comparable in the contemporary and ancient genomes of populations of West Eurasian origin, apparent chronological dynamics were observed, which were characterized by a dramatically lower [T] frequency in samples from ≥10,000 years before present (YBP), as well as a higher frequency in samples between 5,000 and 8,000 YBP (Fig. 1J, lower part; Table S3-S4). Selection and adaptation in response to past pathogen invasions, potentially associated with changes in climate and environment, could be a possible explanation for these dynamics, which have contributed to the differentiated distribution of alleles in different modern ethnic groups [8]. We also evaluated another APOBEC3-variant, the rs12628403, which has important implications in cancer mutagenesis and is similar to rs1014971. It is a proxy for a 30-kb deletion between APOBEC3A and APOBEC3B in non-African populations, and, correlated with the APOBEC-mutagenesis pattern in pan-cancer, represents the strongest signal [19]. Interestingly, the alternative-allele frequency of this variant is also highly heterogeneous across ethnic groups in contemporary populations (TGP data, Fig. S3A). Although it was detected in a few ancient genomes (n = 3 out of 48 samples in the PGG.SNV database, mainly West Eurasia origin; all heterozygous, with the ∼45ka Ust-Ishim individual being the most ancient), due to the lack of data in East Asian samples, its chronological dynamics are yet to be established (Fig. S3B). Additionally, both variants were found to be strong expression-quantitative trait loci (eQTL) of APOBEC3A and APOBEC3B, with the rs12628403 being the most significant for both genes, while the estimated age of the two variants was quite ancient (> ∼20,000 generations equal to roughly > ∼500,000 YBP) (Fig. S3C-D, upper part). These characteristics of the two variants suggested the possible scenario that ancient functional mutations of APOBEC3 enzymes were differentially selected among ethnic groups during diverse local adaptation following varying pathogen exposures, which in turn shaped the contemporary ethnic differences in cancer susceptibility through the modulations of abnormal editing effects on the genomes of somatic cells (similar to the case of the HFE mutations which were involved in Yersinia pestis-driven selection in the past, and which modify iron-metabolism phenotypes in current populations) [9]. The ethnic distribution of the analyzed APOBEC3 variants could be linked with geographic variations in the prevalence of local viral species and the frequency of a certain infection. Nevertheless, although human APOBEC3 genes have been shown to undergo positive natural selection, the impact of population history / genetic drift may also have played a role in shaping the ethnic differentiation of the rs1014971 and APOBEC3A_3B-deletion variants associated with APOBEC-induced somatic mutagenesis and the risk of cancer [20]. Further spatiotemporally-resolved evolutionary analysis of the APOBEC-related genetic variants may lead to a better understanding of their functional roles in both physiological conditions and the carcinogenesis of multiple cancer types. APOBEC3A would be a target of special interest for further investigation, because it plays a major role in somatic deamination among all APOBEC3 enzymes and there is an unexplained significance of the over-representation of ancient mutations among its eQTLs (Fig. S3C, lower part) [21]. Our findings highlighted the significance of evolution-related genetic effects in ethnic differences in the risk of bladder cancer, a malignancy for which genetic heritability is estimated to account for 30% of the variation in susceptibility [22], however, other factors may also play a role in explaining ancestry-specific, age-adjusted incidence rates, such as the differences in smoking habits between different ethnic groups in the US.

CONCLUSIONS

In summary, the present study suggests a possible involvement of APOBEC3-related rs1014971 in the differing BCa incidence across ethnic groups, and such a difference could potentially be the result of human evolution. This adds to the collection of empirical evidence indicating that contemporary, population-level variations in disease susceptibility could be an inherited ‘side-effect’ of pathogen-driven selection in the past. Integrated analysis of cancer genomics and evolutionary-population genetics in large samples might prove to be a powerful, novel approach to further decoding the underlying mechanisms of human carcinogenesis.